Spatial Imaging Reveals Why Antibodies Fail Inside Solid Tumors

A new imaging system maps antibody behavior inside human tumors

Researchers at Vanderbilt University Medical Center and Stanford University developed a single-cell spatial pharmacology (SSP) platform that directly visualizes how therapeutic antibodies move through and engage targets in solid tumors. The work, published in Nature Biotechnology, applies fluorescence imaging and spatial analysis to measure drug distribution, target binding, and physical barriers at cellular resolution.

The team tested the platform on head and neck and pancreatic tumor samples using panitumumab-IRDye800CW, an antibody under investigation for fluorescence-guided surgery. They found pronounced spatial heterogeneity in both drug delivery and target engagement across tumor types. The consistent culprit: stromal architecture—the dense, noncancerous tissue surrounding tumors that acts as a physical barrier limiting antibody penetration.

"Current pharmacology tools and imaging methodologies do not provide the answers we need to understand which drugs fail due to poor delivery and which ones fail due to insufficient activity," said Eben Rosenthal, the study's senior author and chair of otolaryngology at Vanderbilt Health. The platform allows researchers to examine how a drug distributes within a tumor, which cell types it interacts with, how strongly it engages its molecular target, and how the tumor microenvironment shapes delivery and activity.

Distinguishing delivery failure from drug failure matters for trial design

Antibody therapies routinely disappoint in solid tumors despite sound design and clear targets. Until now, oncology teams lacked a diagnostic tool to determine whether a therapy failed because the drug was weak or because it never reached its destination. This distinction is critical: a delivery problem may be solvable with engineering (larger dose, ligand conjugate, prodrug strategy), while a target-engagement problem points to a bad hypothesis.

The SSP platform directly measures these variables in human tissue. By exposing which tumor regions are biologically unresponsive versus simply underexposed to the agent, it can guide decisions to proceed, pivot, or abandon a candidate earlier in development. If the findings scale to larger patient cohorts, the tool could reduce late-stage failures driven by delivery barriers that should have been apparent earlier.

Rosenthal's group notes that additional validation in larger sample sizes will be necessary to establish SSP as a predictive tool for therapy success, but the initial data point to a consistent mechanical problem across tumor types that engineering might address.

How to use this insight in antibody development

Oncology teams designing or evaluating antibody therapies should consider requesting SSP profiling on lead candidates during early clinical stages. The platform's ability to isolate delivery barriers from target-engagement failures can inform decisions to modify dosing, route of administration, or conjugation strategy before entering later-phase trials with larger cohorts and budgets.

For surgical oncology programs already using fluorescence imaging, SSP offers a natural extension: measuring drug kinetics and target engagement in resected tumor tissue can validate fluorescent dyes and predict surgical detection performance. The method is most immediately applicable to programs with phase 1 candidates or those redesigning failed therapies, where stromal barriers are a testable hypothesis.